IsoTis OrthoBiologics
IsoTis OrthoBiologics Announces Final Resolution of AFM Matter
LAUSANNE, Switzerland, and IRVINE, California, September 15 /PRNewswire/ -- IsoTis S.A.
(SWX/Euronext: ISON; TSX: ISO), the orthobiologics company, today announced that the
amount of the fine for the timing of regulatory filings to the AFM regarding the merger
of IsoTis N.V. and IsoTis S.A. (at that time named Modex Therapeutics S.A.) in 2002 has
been set by the administrative Court of Appeal in the Netherlands at EUR 326,715 for
IsoTis N.V. and IsoTis S.A. As previously reported, the Company recorded a provision for
the total amount of the potential liability, EUR 653,430 (EUR 326,715 for each company).
IsoTis OrthoBiologics has a product portfolio with several innovative and proprietary
natural and synthetic bone graft substitutes on the market and others in development, an
established North American independent distribution network, and an expanding
international presence. The company's main commercial operations are based in Irvine, CA,
and its international sales headquarters are based in Lausanne, Switzerland.